The group's principal activity is to develop gene therapy products for the treatment of cancer. The group's product, advexin(R) gene therapy combines the p53 gene to protect cells from becoming cancerous. The major products of the group include ingn 241 (mda-7), ingn 251 (pten) and others. The group has conducted a number of studies to establish the safety and evaluate the efficacy of advexin (R), both alone and in combination with radiation therapy, chemotherapy and surgery. The group has also conducted a phase 1 safety study in 53 patients with end-stage nsc lung cancer, who had failed surgery, radiation and chemotherapy.
